Allgemeine und supportive Therapie der pulmonal arteriellen Hypertonie: Empfehlungen der Kölner Konsensus Konferenz 2016

Zusammenfassung

Die 2015 veröffentlichen Europäischen Leitlinien zur Diagnostik und Therapie der pulmonalen Hypertonie sind nunmehr auch in Deutschland gültig. Die Leitlinien befassen sich eingehend mit der Therapie der pulmonal arteriellen Hypertonie (PAH). Für die praktische Umsetzung der Europäischen Leitlinien in Deutschland sind jedoch zahlreiche für Deutschland spezifische Gesichtspunkte und bereits wieder neue Daten bedeutsam, die eine ausführliche Kommentierung der Leitlinien und in einigen Punkten eine Aktualisierung notwendig machen. Im Juni 2016 fand in Köln eine Konsensuskonferenz statt, die von den Arbeitsgruppen PH der Deutschen Gesellschaften für Kardiologie (DGK), Pneumologie (DGP) und Pädiatrische Kardiologie (DGPK) organisiert wurde. Die Konferenz befasste sich mit der Umsetzung der Europäischen Leitlinien in Deutschland. Dazu wurden verschiedene Arbeitsgruppen eingesetzt, von denen sich eine gezielt der allgemeinen und supportiven Therapie der PAH widmete. Die Ergebnisse und Empfehlungen dieser Arbeitsgruppe werden in dem vorliegenden Manuskript detailliert beschrieben.

Abstract

The 2015 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension are also valid for Germany. The guidelines contain detailed recommendations for the targeted and supportive treatment of pulmonary arterial hypertension (PAH). However, the practical implementation of the European Guidelines in Germany requires the consideration of several country-specific issues and already existing novel data. This requires a detailed commentary to the guidelines, and in some aspects an update already appears necessary. In June 2016, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany. This conference aimed to solve practical and controversial issues surrounding the implementation of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to general and supportive therapy of PAH. This article summarizes the results and recommendations of this working group.

Schlüsselwörter

allgemeine Maßnahmen - supportive Therapie - pulmonal arterielle Hypertonie

Keywords

general measures - supportive therapy - pulmonary arterial hypertension

• Literatur

• 1 Galie N, Humbert M, Vachiery JL et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903-975
• 2 Mereles D, Ehlken N, Kreuscher S et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006; 114: 1482-1489
• 3 de Man FS, Handoko ML, Groepenhoff H et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009; 34: 669-675
• 4 Becker-Grunig T, Klose H, Ehlken N et al. Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. International journal of cardiology 2013; 168: 375-381
• 5 Grunig E, Maier F, Ehlken N et al. Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis research & therapy. 2012; 14: R148
• 6 Nagel C, Prange F, Guth S et al. Exercise training improves exercise capacity and quality of life in patients with inoperable or residual chronic thromboembolic pulmonary hypertension. PLoS One 2012; 7: e41603
• 7 Grunig E, Lichtblau M, Ehlken N et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J 2012; 40: 84-92
• 8 Chan L, Chin LM, Kennedy M et al. Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest 2013; 143: 333-343
• 9 Weinstein AA, Chin LM, Keyser RE et al. Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. Respir Med 2013; 107: 778-784
• 10 Ehlken N, Lichtblau M, Klose H et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J 2016; 37: 35-44
• 11 Yuan P, Yuan XT, Sun XY et al. Exercise training for pulmonary hypertension: A systematic review and meta-analysis. International journal of cardiology 2014; 178c: 142-146
• 12 Pandey A, Garg S, Khunger M et al. Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis. Circulation Heart failure. 2015; 8: 1032-1043
• 13 Buys R, Avila A, Cornelissen VA. Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. BMC Pulm Med 2015; 15: 40
• 14 Jais X, Olsson KM, Barbera JA et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J 2012; 40: 881-885
• 15 Duarte AG, Thomas S, Safdar Z et al. Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience. Chest 2013; 143: 1330-1336
• 16 Thorne S, Nelson-Piercy C et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care 2006; 32: 75-81
• 17 Bendayan D, Hod M, Oron G et al. Pregnancy outcome in patients with pulmonary arterial hypertension receiving prostacyclin therapy. Obstet Gynecol 2005; 106: 1206-1210
• 18 Bonnin M, Mercier FJ, Sitbon O et al. Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology 2005; 102: 1133-1137
• 19 Zengin E, Sinning C, Schrage B et al. Right heart failure in pregnant women with cyanotic congenital heart disease – The good, the bad and the ugly. International journal of cardiology 2016; 202: 773-775
• 20 Olsson KM, Jais X. Birth control and pregnancy management in pulmonary hypertension. Seminars in respiratory and critical care medicine 2013; 34: 681-688
• 21 Meyer S, McLaughlin VV, Seyfarth HJ et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J 2013; 41: 1302-1307
• 22 Olofsson C, Bremme K, Forssell G et al. Cesarean section under epidural ropivacaine 0.75 % in a parturient with severe pulmonary hypertension. Acta Anaesthesiol Scand 2001; 45: 258-260
• 23 Raines DE, Liberthson RR, Murray JR. Anesthetic management and outcome following noncardiac surgery in nonparturients with Eisenmenger’s physiology. J Clin Anesth 1996; 8: 341-347
• 24 Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223
• 25 Guillevin L, Armstrong I, Aldrighetti R et al. Understanding the impact of pulmonary arterial hypertension on patients’ and carers’ lives. Eur Respir Rev 2013; 22: 535-542
• 26 Lowe B, Grafe K, Ufer C et al. Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 2004; 66: 831-836
• 27 Halank M, Speich R, Petkova D et al. Lebensqualität bei pulmonal arterieller und chronisch thromboembolischer pulmonaler Hypertonie. Dtsch med Wochenschr 2014; 139: S126-135
• 28 Harzheim D, Klose H, Pinado FP et al. Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Res 2013; 14: 104
• 29 Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med 2000; 343: 1942-1950
• 30 Ladwig KH, Lederbogen F, Albus C et al. Position paper on the importance of psychosocial factors in cardiology: Update 2013. Ger Med Sci 2014; 12: Doc09
• 31 Larisch A, Neeb C, de Zwaan M et al. Psychische Belastung und Psychosomatischer Behandlungswunsch von Patienten mit Pulmonaler Hypertonie. Psychother Psych Med 2014; 64: 384-389
• 32 Weitzenblum E, Sautegeau A, Ehrhart M et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131: 493-498
• 33 Burns RM, Peacock AJ, Johnson MK et al. Hypoxaemia in patients with pulmonary arterial hypertension during simulated air travel. Respir Med 2013; 107: 298-304
• 34 Fuster V, Steele PM, Edwards WD et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587
• 35 Huber K, Beckmann R, Frank H et al. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994; 150: 929-933
• 36 Herve P, Humbert M, Sitbon O et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clinics in chest medicine. 2001; 22: 451-458
• 37 Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998; 12: 1446-1449
• 38 Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81
• 39 Olsson KM, Delcroix M, Ghofrani HA et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014; 129: 57-65
• 40 Galiè ND, Ghofrani HA, Jansa P et al. Anticoagulant therapy does not influence long-term outcomes in patients with pulmonary arterial hypertension (PAH): insights from the randomised controlled SERAPHIN trial of macitentan. Eur Heart J 2014; 35 (Suppl 1) 10
• 41 Preston IR, Roberts KE, Miller DP et al. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation 2015; 132: 2403-2411
• 42 Cohn JN. Optimal diuretic therapy for heart failure. Am J Med 2001; 111: 577
• 43 Maron BA, Waxman AB, Opotowsky AR et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol 2013; 112: 720-725
• 44 Rabinovitz A, Raiszadeh F, Zolty R. Association of hyponatremia and outcomes in pulmonary hypertension. Journal of cardiac failure 2013; 19: 550-556
• 45 Sandoval J, Aguirre JS, Pulido T et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001; 164: 1682-1687
• 46 Hildenbrand FF, Bloch KE, Speich R et al. Daytime measurements underestimate nocturnal oxygen desaturations in pulmonary arterial and chronic thromboembolic pulmonary hypertension. Respiration; international review of thoracic diseases. 2012; 84: 477-484
• 47 Ulrich S, Keusch S, Hildenbrand FF et al. Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre-capillary pulmonary hypertension and sleep-disturbed breathing: randomized, double-blind, cross-over trial. Eur Heart J 2013; 36: 615-623
• 48 Rich S, Seidlitz M, Dodin E et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998; 114: 787-792
• 49 Ghofrani HA, Distler O, Gerhardt F et al. Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011; 154: S20-33
• 50 Ruiter G, Lankhorst S, Boonstra A et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J. 2011; 37: 1386-1391
• 51 Ruiter G, Lanser IJ, de Man FS et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology 2014; 53: 285-292
• 52 Broberg CS, Jayaweera AR, Diller GP et al. Seeking optimal relation between oxygen saturation and hemoglobin concentration in adults with cyanosis from congenital heart disease. Am J Cardiol 2011; 107: 595-599
• 53 Rhodes CJ, Howard LS, Busbridge M et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol 2011; 58: 300-309
• 54 Van De Bruaene A, Delcroix M, Pasquet A et al. Iron deficiency is associated with adverse outcome in Eisenmenger patients. Eur Heart J 2011; 32: 2790-2799
• 55 Viethen T, Gerhardt F, Dumitrescu D et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol 2014; 175: 233-239
• 56 Kaemmerer H, Fratz S, Braun SL et al. Erythrocyte indexes, iron metabolism, and hyperhomocysteinemia in adults with cyanotic congenital cardiac disease. Am J Cardiol 2004; 94: 825-828
• 57 Tongers J, Schwerdtfeger B, Klein G et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007; 153: 127-132
• 58 Hoeper MM, Galie N, Murali S et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002; 165: 341-344
• 59 Showkathali R, Tayebjee MH, Grapsa J et al. Right atrial flutter isthmus ablation is feasible and results in acute clinical improvement in patients with persistent atrial flutter and severe pulmonary arterial hypertension. Int J Cardiol 2011; 149: 279-280
• 60 Bandorski D, Bogossian H, Braun O et al. Patients with atrial fibrillation complicated by coronary artery disease. Is a single value of sensitive cardiac troponin I on admission enough? Herzschrittmacherther Elektrophysiol 2015; 26: 39-44
• 61 Rajdev A, Garan H, Biviano A. Arrhythmias in pulmonary arterial hypertension. Prog Cardiovasc Dis 2012; 55: 180-186
• 62 Luesebrink U, Fischer D, Gezgin F et al. Ablation of typical right atrial flutter in patients with pulmonary hypertension. Heart Lung Circ 2012; 21: 695-699